ILMN vs. ONC: Illumina vs. BeOne Medicines Stock Comparison

Company Profile

Illumina (ILMN) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.

Illumina (ILMN) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while BeOne Medicines (ONC) is defensive at 0.59 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Illumina (ILMN) at 32.39% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Illumina (ILMN) at 19.72% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.

Both Illumina (ILMN) at 20.02% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BeOne Medicines (ONC) at 40.23% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Illumina (ILMN) nor BeOne Medicines (ONC) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Illumina (ILMN) at 2.63 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Illumina (ILMN) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Illumina (ILMN) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Illumina (ILMN) at 36.68 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Illumina (ILMN) at 7.10 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both Illumina (ILMN) at 10.30 and BeOne Medicines (ONC) at 7.98 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics